Develop and register acoziborole as a new, single-dose, oral treatment.
current phase of drug development
updated 29 Feb 2020
Acoziborole was selected as a pre-clinical candidate for g-HAT in late 2009. This resulted from DNDi’s own lead optimization project starting with an initial hit identified in the Anacor chemical library. In 2012, it became DNDi’s first new chemical entity resulting from its own lead optimization programme to enter clinical development.
The delivery of fexinidazole has improved therapeutic options for people with sleeping sickness. But the development of an additional, oral treatment, especially one that could be given as a one-day, one-dose treatment, could provide even better options, as well as supporting efforts to eliminate and sustain elimination of the disease.
Get our latest news, personal stories, research articles, and job opportunities.